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2 
Abstract:   25 
Introduction: Hypercortisolism in Cushing's syndrome(CS) is associated with increased morbility and 26 
mortality. Hypercortisolism also occurs in chronic depressive disorders and stress, where telomere 27 
length(TL) is shorter than in controls. We hypothesized that telomere shortening might occur in CS and 28 
contribute to premature aging and morbidity. 29 
 30 
Aim: investigate TL in CS compared to controls. 31 
 32 
Methods: Seventy-seven CS patients (14 males, 59 pituitary, 17 adrenal, 1 ectopic; 21 with active disease) 33 
were compared to 77 gender-, age- and smoking- matched controls. 15 CS were evaluated longitudinally, 34 
during active disease and after remission of hypercortisolism. Leukocyte TL was measured by TRF-Southern 35 
technique. Clinical markers were included in a multiple linear regression analysis to investigate potential 36 
predictors of TL.  37 
 38 
Results: Mean TL in CS and controls was similar (7667 base pairs-bp- vs 7483,NS). After adjustment for 39 
age, in the longitudinal evaluation, TL was shorter in active disease than after remission (7273 vs 40 
7870,p<0.05). Age and dyslipidemia were negative predictors(p<0.05), and total leukocyte count a positive 41 
predictor for TL(p<0.05). As expected, a negative correlation was found between TL and age (CS r-0.4 and 42 
controls r-0.292,p<0.05). No correlation was found between circulating cortisol, duration of exposure to 43 
hypercortisolism or biochemical cure and TL.   44 
 45 
Conclusion: Even though in the cross-sectional comparison of CS and controls no difference in TL was 46 
found, in the longitudinal evaluation, patients with active CS had shorter TL than after biochemical cure of 47 
hypercortisolim. These preliminary results suggest that hypercortisolism might negatively impact on 48 
telomere maintenance.  Larger group of patients are needed to confirm these finding. 49 
 50 
3 
Introduction 51 
Cushing's syndrome (CS), a rare disease due to excessive cortisol secretion, is associated with increased 52 
mortality and severe morbidity (increased cardiovascular risk and fatigability, osteopenia, 53 
neuropsychological alterations and impaired health-related quality of life- HRQoL), not completely 54 
reversible after biochemical control (1). The mechanisms by which these abnormalities do not recover 55 
completely appear to be complex and are not currently well understood. Hyperstimulation of the 56 
hypothalamic-pituitary-adrenal axis also resulting in hypercortisolism may also occur in psychiatric diseases 57 
like acute and chronic stress and post-traumatic stress disorder (2,3). These situations are associated with 58 
poor health indexes and telomere length (TL) has been found to be shorter than in matched controls (4).  59 
Telomeres are repetitive DNA sequences, located at the end of linear chromosomes, essential to maintain 60 
genomic stability. Without telomeres, genetic material could be lost after every cell division; thus, when 61 
telomeres are critically short, cell division stops and senescence and apoptosis are induced (5). To avoid 62 
telomere attrition and to maintain TL, germ-line cells and a few somatic cells produce an enzymatic complex 63 
called telomerase. Telomerase function can be regulated by genetic, epigenetic, environmental and hormonal 64 
factors (5). These include mainly stress hormones such as cortisol, catecholamines, estrogens and growth 65 
factors.  66 
In this line, accelerated telomere shortening, higher levels of urinary catecholamines and free urinary cortisol 67 
have been observed in situations with high perceived psychological stress (in sisters of patients with cancer, 68 
in acute mental stress) (6). In vitro studies have shown a 50% reduction of telomerase activity in 69 
lymphocytes after exposure to high levels of hydrocortisone (7) and a rapid and dynamic loss of telomeric 70 
sequences after exposure of mice thymocytes to dexamethasone (8). Shorter leukocyte TL has been described 71 
associated with elevated cortisol responses and dysregulated patterns of daily cortisol secretion in women 72 
who are patient caregivers (9).  Recently, a longitudinal study evaluating the association between coexisting 73 
changes in cortisol and telomerase activity in peripheral blood mononuclear cells (PBMCs) has been 74 
published (10). The authors examined whether participation in mindfulness-based interventions and 75 
improvements in psychological distress and metabolic factors were associated with increases in telomerase 76 
activity. They observed that serum cortisol levels were negatively correlated with changes in telomerase 77 
activity, suggesting that changes in stress-related cortisol might be one of the signals regulating telomerase 78 
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levels in humans.  79 
This evidence led us to hypothesize that telomere shortening may be behind the increased morbidity and 80 
features of premature ageing in patients with CS. Hypercortisolemia could contribute to premature ageing by 81 
inducing accelerated telomere shortening, which in turn could be implied in the persistent morbidity and 82 
clinical consequences associated with CS, even years after  biochemical remission. Since TL is an indicator 83 
of chromosome stability, proliferative capacity and cellular ageing, measuring TL could contribute to the 84 
understanding of its clinical and biological significance. To the best of our knowledge, telomere dysfunction 85 
has not been evaluated in CS patients before.  86 
The aim of this study was to investigate TL in patients diagnosed with CS compared to sex-, age- and 87 
smoking- matched healthy controls and to evaluate whether normalization of the hypothalamic-pituitary-88 
adrenal axis after treatment reverses possible abnormalities.  89 
 90 
SUBJECTS AND METHODS 91 
Subjects 92 
In this case-control study, patients with endogenous CS followed in our institution since 1982 were eligible. 93 
Patients with adrenal carcinoma were excluded. Seventy-seven CS patients and 77 controls, matched for 94 
gender, age and smoking participated in the study. Fourteen were men (18.2%) and 63 women (81.8%). 95 
Mean age at the time of the study was 48.6±12.8 years.  Fifty-nine patients were of pituitary origin (76.6%), 96 
17 of adrenal origin (adrenal adenoma or bilateral macronodular hyperplasia) and in one patient the origin 97 
was unknown (ectopic ACTH secretion of unknown source). Twenty-one patients (27.3%) had active disease 98 
at the time of the study and 56 (72.7%) were cured; mean time of remission of hypercortisolism was 6.4±7.2 99 
years. Eight active CS patients (38%) were treated with metyrapone, 6 (28.5%) with ketoconazole and 3 100 
(14.2%) with both drugs. Mean duration of endogenous hypercortisolism was 72 months (range 11-264). 101 
Duration of hypercortisolism was considered as the period between onset of symptoms (as referred by the 102 
patients) and remission of hypercortisolism (in patients in remission) or the time of current analysis (in active 103 
patients). The period between onset of symptoms and biochemical diagnosis of CS was 34 months (range 3-104 
120). Twenty-two patients (28.6%) had received pituitary radiotherapy and 71 (92.2%) had undergone 105 
surgery. Fifty-three % (n=41) were cured after initial treatment and had no recurrence and 19.5% (n=15) 106 
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were cured after further therapies for recurrent disease. Fifteen cured patients (19.5%) were adrenal 107 
insufficient at the time of telomere analysis and required substitution therapy with hydrocortisone (mean 108 
dose 17.6±3.7 mg, range 10-20). Nine (11.7%) patients were GH-deficient (4 of which were replaced with 109 
recombinant human GH); 8 women (10.4%) were gonadotropin-deficient (all on estrogen/progesterone 110 
hormone replacement therapy), and 15 patients (19.4%) were hypothyroid, 10 due to TSH deficiency and 5 111 
due to primary hypothyroidism (all on L-thyroxine replacement). CS was considered in remission if either 112 
adrenal insufficiency was demonstrated (basal morning cortisol < 100 nmol/l [<4µg/dl] and/or undetectable 113 
24-h free urinary cortisol) or morning cortisol suppression (<50 nmol/l, < 1.8 µg/dl) after 1 mg 114 
dexamethasone overnight was observed. Twenty-five patients (32%) were on antihypertensive medication, 115 
17 (22%) on statin treatment for dyslipidemia, and 12 (16%) were treated with calcium and vitamin-D. 116 
In a subgroup of 15 CS (all women) patients studied initially with active disease, a second analysis of TL 117 
was performed once they were in remission. In this longitudinal study, 3 were of adrenal origin and 12 of 118 
pituitary origin. Mean age at the time of active disease was 43.5±12.1 years and at remission was 46.6±11.3 119 
years. The time elapsed between both analyses was 40.1±15.6 months and mean time of remission was 120 
28.5±14.1 months. Three cured patients (20%) were adrenal insufficient at the time of telomere analysis and 121 
required substitution therapy with hydrocortisone (mean dose 18.3±2.2mg, range 10-20); 4 patients (26.6%) 122 
were hypothyroid, 2 due to TSH deficiency and 2 due to primary hypothyroidism (all on L-thyroxine 123 
replacement). None of the cured patients were GH-deficient; 7 women (46.6%) were postmenopausal at 124 
remission but no gonadotropin-deficiency was observed (n=8).  125 
 126 
Seventy-seven controls selected from the blood bank donor’s database or from healthy volunteers recruited 127 
among hospital employees were matched for gender, age and smoking status, three features known to affect 128 
TL. Namely, age is an important determinant of TL, typically decreasing with advancing age (11). Females 129 
usually present longer TL than males, since estrogens stimulate telomerase activity and protect DNA from 130 
reactive oxygen species (ROS)-induced damage (12). Cigarette smoke constituents increase cumulative and 131 
systemic oxidative stress and inflammation, which induce increased white blood cell turnover, resulting in 132 
accelerated TL shortening (13). Medical history and physical examination excluded any who reported 133 
glucocorticoid exposure, severe and/or acute diseases and severe psychiatric alterations (however, anxiety 134 
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and mild depression were not exclusion criteria). Four controls (5.7%) were on antihypertensive therapy, 135 
another 4 (5.7%) were receiving statin treatment for dyslipidemia, and 3 (4.3%) were treated with calcium 136 
and vitamin-D. 137 
 138 
Anthropometry (weight, height, body mass index and waist/hip ratio) was measured in patients and controls. 139 
Hypertension was defined as systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg or 140 
the use of antihypertensive medications. Dyslipidemia was defined as total cholesterol (TC) >220 mg/dl, 141 
low-density lipoprotein (LDL) >130 mg/dl, triglyceride levels ≥150 mg/dl or treatment with lipid-lowering 142 
medication. Diabetes mellitus was confirmed with fasting glucose levels >126 mg/dL in two consecutive 143 
determinations or 2-hour glucose after OGTT >200 mg/dL. Adult patients were considered osteopenic when 144 
T score was <-1 and >-2.5 or osteoporotic when T score was <-2.5 SD.  145 
All participants provided a blood sample for DNA extraction and gave their informed consent. The study was 146 
approved by the hospital ethics committee.  147 
 148 
Methods 149 
Genomic DNA extraction from total leukocytes was performed using an adapted Proteinase K and Phenol 150 
protocol (14). Blood samples from the patients were collected in EDTA tubes to reduce DNA degradation. 151 
Genomic DNA was isolated from blood buffy coats. The buffy coat and white blood cell pellets were stored 152 
frozen at -80°C prior to processing. The white bood cell layers were harvested and digested with buffer 153 
containing 0.1 M MgCl2, 0.02 M EDTA, 0.5% SDS, 0.01 M Tris, pH 8.0, and 1 mg/mL of proteinase K at 154 
37°C overnight. The lysates were homogenized by passes through a blunt 20-gauge needle (0.9 mm 155 
diameter) at 4ºC temperature and DNA was purified by phenol:chloroform:isoamilic alcohol (25:24:1) 156 
extraction, and ethanol precipitation. Finally, genomic DNA was dissolved in Tris-EDTA buffer and was 157 
quantified by spectrophotometric analysis. The quality of genomic DNA was checked for high molecular 158 
weight by 1% agarose gel electrophoresis.  159 
 160 
TL measurements were performed by the telomere restriction fragment assay (TRF) using the Telo TAGGG 161 
Telomere Length Assay Kit (Roche 12209136001). Briefly, 1 µg of DNA was digested with 20 units of Rsal 162 
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and Hinfl for 2 h at 37ºC. Samples were loaded on a 0.5% Seakem® Gold Agarose gel and were run for 21 h 163 
at 35 V. Gels were treated with HCl, denaturalized and neutralized, and then transferred to a nylon membrane 164 
by capillarity for 12-18 h. After fixation with UV, hybridization was carried out with a DIG-labelled 165 
telomeric probe (3 h at 42ºC). Finally, restriction washes, incubation with anti-DIG-AP antibody and 166 
detection by chemiluminiscence was carried out. Images were analysed with the program Quantity One. TRF 167 
mean was calculated using the formula: TRF mean = ∑ODi/∑(ODi/Li), where ODi is the chemiluminiscent 168 
signal and Li is the length of the TRF fragment at position i (15). The accuracy of Southern Blot technique is 169 
up to ± 300 base pairs (16). A control sample, 2 µg of digested DNA derived from a single batch of Hela 170 
cells, was run on each gel to minimize interassay variation. The mean TL for Hela cells was 4113bp with a 171 
standard deviation of ±210bp, which is in the range of the accuracy of Southern Blot technique.   172 
 173 
Biochemical, hormone and bone analyses 174 
Routine serum determinations were performed by standard automated laboratory methods: fasting glucose, 175 
total cholesterol, high and low-density lipoprotein (HDL/LDL) cholesterol and triglyceride levels. Blood 176 
counts were performed using automated cell counters. Twenty-four-hour urinary free cortisol was measured 177 
with a commercial RIA with prior extraction with an organic solvent. Plasma ACTH, serum cortisol and IGF-178 
1 levels were measured using a commercial chemiluminiscent immunometric assay. Lumbar spine and whole 179 
body bone mineral density and content (BMD and BMC) were measured by DXA scanning (Delphi QDR 180 
4500; Hologic); the mean precision error (CV) was 1%. 181 
 182 
Statistical analysis 183 
Statistical analyses were performed using the SPSS 19.0 statistical package for Windows (SPSS Inc, Chicago 184 
Illinois).  Initially a descriptive analysis of all variables was performed in order to verify correct introduction 185 
of data in the database. Quantitative data are expressed as mean and SD (Gaussian distribution) or as median 186 
and range (non-Gaussian distribution), and categorical data are expressed as percentages. Data distribution 187 
was analyzed by the Kolmogorov-Smirnov test. TL variable was normally distributed. Logarithmic 188 
transformations were performed where necessary to normalize the distribution of a particular measure.  189 
Comparison between 2 groups was performed using Student’s t (Gaussian distribution) or Mann-Whitney’s 190 
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U (non-Gaussian distribution) tests. A Chi-square test was performed for categorical variables. Fisher exact 191 
test was performed when appropriate. Pearson’s correlation coefficient was used to estimate linear 192 
association between two quantitative variables. Analysis of covariance (ANCOVA) was performed to 193 
evaluate TL after adjustment for age and for total leukocyte count (as covariates). Multiple linear regression 194 
analysis including age, gender, body mass index, T2DM, dyslipidemia, hypertension, psychiatric history, 195 
duration of hypercortisolism, current hypercortisolism, total leukocytes and 24 hour urinary free cortisol as 196 
potential predictive factors for TL (as dependent variable) was performed.  197 
P values < 0.05 were considered significant.  198 
 199 
RESULTS 200 
Comparison between CS and matched controls (Tables 1 and 2).  201 
Main baseline characteristics of CS patients and controls are summarized in table 1. CS patients had more 202 
hypertension, diabetes, dyslipidemia and osteoporosis than their matched controls (p<0.05). Mean TL values 203 
in CS and controls are summarized in Figure 1. No differences were observed between males and females 204 
(7732±1242 vs. 7540±1361 bp, respectively). TL did not differ between CS and controls (7667±1260 vs. 205 
7483±1214, respectively, ns). TL did not differ between active CS, cured CS (with or without secondary 206 
adrenal insufficiency) and their matched controls (Figure 1).  207 
As expected, a negative linear correlation between age and TL in the whole sample was observed (R = -208 
0.341, p <0.001). When both groups were evaluated separately, this negative correlation was maintained in 209 
CS patients (R = -0.400, p < 0.001) and in controls (R = -0.292, p < 0.01) (Figure 2). A positive correlation 210 
was found between IGF-1 and TL in CS patients (R = 0.331, p < 0.05), but was not correlated with the 211 
presence or absence of GH deficiency or rhGH replacement therapy. No differences in TL were observed 212 
related to the presence of pituitary deficiencies and/or replacement therapies either. No correlation was 213 
observed between duration of hypercortisolism and TL (R = -0.025, p NS), or between morning serum 214 
cortisol (R = 0.047, p NS), 24 hour urinary free cortisol (R=0.072, p NS) or plasma ACTH (R=0.192, p NS) 215 
and TL. In active CS patients, we did not observed differences in TL according to steroidogenesis inhibitors 216 
we used (metyrapone 8258±1178 vs ketoconazole 7896±1432, NS). 217 
In the multiple linear regression analysis performed to identify potential predictive factors of TL, we 218 
9 
observed that age and dyslipidemia were negative predictive factors for TL shortening (p=0.006 and p 0.017, 219 
respectively), while total leukocyte count was a positive predictor for TL  (p=0.043) (R
2
 0.23), indicating that 220 
more leukocytes were associated with longer TL. The main leukocyte cell subtypes count (neutrophils and 221 
lymphocytes) differed between active CS patients and controls (Table 2), but not between cured CS patients 222 
and their healthy controls. After adjustment for total leukocyte count as covariate, no differences in TL 223 
between the 21 active CS and their controls were observed either (7600±1197 vs 7450±1274, p NS). 224 
 225 
Longitudinal analysis in CS patients evaluated both during active disease and in remission  226 
As expected, patients were older once remission was attained. Ten patients (66%) clearly showed an 227 
increment of TL upon remission of CS. In 5 (33%) TL decreased after remission (Figure 3), but was minimal 228 
in 2 and of doubtful relevance, since it was around the detection limit of 300 bp (around 4%) TL’s variation 229 
in our population (20). Moreover, after adjustment for age as covariate, TL was shorter in active disease than 230 
after remission (7273±1263 vs. 7870±1039, respectively, p<0.05) in the same patients (figure 3), in sharp 231 
contrast with TL shortening usually observed as age increases. No significant differences in the presence of 232 
hypertension, dyslipidemia, diabetes or use of medications were observed between the group of patients who 233 
increased their TL during remission and those who did not increase TL. Patients who incremented TL, also 234 
decreased their body mass index more after remission than those who did not increase TL (-2.3 kg/m
2
 vs. -235 
0.8 kg/m
2
) although due to the small group size, it did not reach statistical significance (p = 0.19). A trend for 236 
a positive correlation between TL at remission and duration of remission was also seen (R = 0.494, p=0.061). 237 
 238 
DISCUSSION 239 
To the best of our knowledge, this is the first study to evaluate TL in this rare disease and with a relatively 240 
large series of CS patients. When investigated longitudinally, our preliminary data show that patients with 241 
active CS have a shorter TL, which become longer after hypercortisolism disappeared with effective 242 
treatment. However, in the cross-sectional case-control study comparing all patients with CS and matched 243 
controls, no differences in TL were found. This was also the case when patients with active hypercortisolism, 244 
and those considered in remission (with or without concomitant adrenal insufficiency) were compared with 245 
their respective matched controls.  246 
10 
CS patients provide a unique opportunity to examine the effects of hypercortisolism on telomere 247 
maintenance. CS determines increased morbidity and mortality, especially in the untreated state but also after 248 
therapy when compared to background population (1, 17). Severe morbidities are also increased even in the 249 
3 years prior to diagnosis when compared to normal population, and are not completely reversible after 250 
endocrine cure (17). The mechanisms by which CS patients do not recover completely after biochemical 251 
remission are still unknown. It is possible that telomere dysfunctions partially contribute to these 252 
abnormalities. In other situations where hypercortisolim is often present such us chronic stress and some 253 
psychiatric conditions, TL has been found to be shorter than in matched controls (6,9). These previous 254 
evidences took us to hypothesize that TL shortening could contribute to the increased morbidity and features 255 
of premature ageing observed in endogenous hypercortisolism of CS. Thus, we planned this study in order to 256 
investigate the telomere system in these patients.   257 
We have evaluated a significant number of CS patients (n=77), a rare disease with an incidence ranging from 258 
0.7 to 2.4 cases per million inhabitants per year (18). They were carefully matched for age, gender and 259 
smoking status with controls. These relatively small groups may contribute to explain why no differences in 260 
TL were observed between CS and controls. Furthermore, many other factors apart from hypercortisolism 261 
may affect TL, both individual and environmental (genetic, epigenetic, socio-economic status, lifestyle, 262 
growth factors, etc) (5). Additionally, TL may be affected by what is known as a “pseudolengthening” 263 
mechanism (19); specifically, TL of lymphocytes becomes increasingly shorter than those of granuylocytes 264 
over the years (20). And since a redistribution of leukocyte cell type is often seen in hypercortisolism 265 
(lymphopenia and neutrophilia) this may also affect the measured TL obtained from the total leukocyte count 266 
(21). In fact, we did find that in active disease total leukocyte and neutrophil counts were higher and 267 
lymphocytes lower than in matched controls.  We observed that total white blood cell counts in each 268 
individual blood sample also affected TL, and CS patients had higher total leukocyte counts compared to 269 
healthy controls, similar to other series (21). However, after adjustment for total leukocyte count (as a 270 
covariate) no differences in TL between CS and their healthy controls were identified.  271 
In the multiple regression analysis, leukocytes count together with age and the presence of dyslipidemia were 272 
predictive factors for TL, explaining 23 percent of the TL present in our CS patients. Not surprisingly, age 273 
was a negative predictive factor for TL, in the whole sample and in the different subgroups analysed. A 274 
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positive correlation was also seen between IGF1 levels and TL, as described in healthy population (11, 22). 275 
Both findings support the reliability and validity of our results and the methodology used, since similar 276 
correlations have been described in much larger populations (but not in CS patients)(14); namely TL was 277 
positively correlated with serum IGF1 and negatively associated with age in a cohort of 476 healthy  278 
Caucasians aged 16-104 years (22). We also observed a negative correlation between TL and dyslipidemia as 279 
described in other paradigms, where cholesterol has been associated with faster biological aging (23).  280 
As expected, some baseline characteristics differed between CS and controls, such as serum morning cortisol 281 
and 24 hour urinary free cortisol, certain cardiovascular risk factors and psychiatric conditions (anxiety and 282 
depression), which were more prevalent in CS patients. Most of these features have recently been related to 283 
telomere dysfunctions (9, 24), although not all results published in the literature are concordant (25). Even 284 
though in the case-control regression analysis they did not seem to have impacted on TL with the exception 285 
of dyslipidemia which negatively affected TL, we can not rule out that in much larger studies some of these 286 
clinical features could determine TL in some way or another. We did not find any influence of medical 287 
treatment to reduce cortisol during active disease or glucocorticoid replacement in patients with adrenal 288 
insufficiency after CS therapy on TL. 289 
The longitudinal analysis of 15 patients evaluated both during hypercortisolism and in remission, adjusting 290 
for age (as a covariate), confirmed our initial hypothesis, since patients with hypercortisolism during active 291 
disease did have shorter telomeres than later in remission (average 596 bp). In spite of being 40.1±15.6 292 
months older at remission, TL was longer and positively associated with duration of remission. Although this 293 
finding is very preliminary based on a small number of patients, which makes difficult to reach firm 294 
conclusions, it would support our initial hypothesis of a negative effect of a hyperactive hypothalamic-295 
pituitary-adrenal axis on TL and cell senescence observed in other studies. Accelerated telomere shortening 296 
was observed in a group of 647 women (who had a sister with breast cancer) with higher perceived stress and 297 
higher levels of urinary free cortisol and cathecolamines (6). Similarly, shorter buccal cell TL was observed 298 
in children exposed to laboratory stressors with higher levels of salivary cortisol and higher autonomic 299 
reactivity (26). Greater cortisol responses and dysregulated patterns of daily cortisol secretion were 300 
associated with shorter leukocyte TL in 14 postmenopausal women caregivers of a partner with dementia 301 
compared to matched noncaregiver controls (27). Consistent with this and with our longitudinal results, one 302 
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in vitro study observed how exposure to high hydrocortisone levels comparable to those that might be 303 
reached in vivo during stress, reduced telomerase activity in lymphocytes (7). As the major pathway for 304 
telomere lengthening seems to be through telomerase activation, this could explain why a patient could have 305 
shorter TL during hypercortisolism. It is probably that when cortisol normalizes, a recovery of telomerase 306 
activity takes place, increasing TL or lowering attrition rates.  307 
Contrary to this evidence and to our results, a recent publication showed telomere shortening associated with 308 
hypocortisolism was observed in patients with high levels of chronic stress exposure or high degrees of 309 
inflammation which could lead to an exhaustion of the HPA axis. It is difficult to identify the mechanism 310 
responsible for accelerated telomere shortening in hypocortisolism, often preceded by a hypercortisolaemic 311 
phase in long-term chronic stress exposure, suggesting that TL could be a measure of cumulative stress (28). 312 
We found no differences in TL in our hypocortisolaemic patients compared to cured patients without 313 
secondary adrenal insufficiency; an explanation could be that all adrenal insufficient patients were correctly 314 
replaced with hydrocortisone.  315 
Lifestyle modifications like increased physical activity after remission may also increase TL, as reported in 316 
some studies, by inducing changes in telomerase activity. The mean fall in BMI in patients who increased TL 317 
was greater than in those who decreased TL after remission (-2.3 kg/m
2
 vs. -0.8 kg/m
2
), but did not reach 318 
statistical significance, probably due to the small sample size in the longitudinal evaluation. This change in 319 
BMI may contribute to explain the increase in TL in cured patients, similarly that seen in a recent 320 
longitudinal intervention study with Mediterranean diet, where BMI was inversely correlated with changes 321 
TL (29).    322 
A model of dynamic telomere balance under stress has been suggested, in which severe stress first would 323 
lead to increased turnover and depletion of circulating cells followed by a compensatory re-population when 324 
stress ends (in short stress conditions). This model could also be present in CS patients, but has to be 325 
confirmed.  It would appear to be important to distinguish between true reversal of telomere shortening and 326 
replenishment by younger cells (“pseudo-lengthening”) that probably takes place in CS after remission (19).  327 
The study has several limitations. The sample size, although respectable considering that CS is a rare disease, 328 
precludes any analysis in different etiological subgroups of CS. This also did not allow to control for all 329 
potential confounders especially medical treatment during active disease, physical activity, current stress, etc.  330 
13 
Especially in hypocortisolemic patients after surgery for CS a perfect cortisol replacement is an elusive goal. 331 
Although the results of the longitudinal evaluation are the opposite to what is expected by increasing age and 332 
it is an interesting result, this finding is certainly preliminary based on a small group of patients. We could 333 
not include the remaining 6 active patients, because 4 of them still present active disease and we lost the 334 
follow up in two patients. A larger group of patients, as well as a larger group of patients followed 335 
longitudinally would clearly strengthen the conclusion of our preliminary findings. White blood cells, the 336 
most characterized tissue source for telomere studies, easily obtainable from peripheral blood, may vary in 337 
their cell type’s distribution in blood as seen in CS patients. TL variability even in the same cell and for 338 
individuals of similar age complicates any conclusions on telomere biology in CS patients (30). Most studies 339 
on telomere biology and ageing are much larger and cross-sectional but large scale, longitudinal, prospective 340 
and well-designed studies are lacking.  It would be interesting to evaluate TL in other tissues such as the 341 
pituitary or the adrenal in CS, since glucocorticoids  induce changes in the immune system; however, this 342 
would be even more difficult than obtaining peripheral leukocytes for TL evaluation. As well as, we could 343 
not measure telomerase activity, which probably could provide a more direct approach on both telomere 344 
system and its dynamics. 345 
The main conclusion of this study is that in individual CS patients in whom hypercortisolism is controlled 346 
after successful treatment, TL increases despite being on average 3 years older. It would appear, therefore, 347 
that telomerase activity would be induced once hypercortisolism disappears, and this could be one of the 348 
mechanisms by which increased morbidity, mortality and biological ageing improve when disease is 349 
controlled. However, in the entire group of CS patients no difference in TL was observed when compared to 350 
healthy controls, pointing to the fact that many other factors determine TL apart from age, including 351 
dyslipidemia, healthier life-styles or differences in leukocyte subsets cell counts. Larger prospective studies 352 
are required to confirm these changes in TL in CS and investigate implications of these abnormalities further.  353 
 354 
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 382 
FIGURE LEGENDS:  383 
Figure 1. Telomere length (TL ) in the whole group of Cushing's syndrome (CS) patients and controls 384 
(7667±1260 vs 7483±1214 bp.), as well as in patients with active CS (7943±1309 vs 7230±1591 bp.), cured 385 
CS without (7510±1219 vs 7639±1335 bp.) or with adrenal insufficiency (AI) (7727±1323 vs 7394±1411 386 
bp.) compared with their respective matched controls. No differences were observed. * Abbreviations: CS, 387 
Cushing's syndrome; AI, adrenal insufficiency; TL, telomere length. 388 
 389 
Figure 2. Telomere length in relation to age in patients with Cushing’s syndrome (•) and controls (◦). 390 
Telomere length is shortened with advancing age in both CS (R = -0.400, p <0.001) and controls (R = -0.292, 391 
p <0.01). *Abbreviations: bp. base pairs. 392 
 393 
Figure 3. 3A: Changes in telomere length (TL) in 15 patients in whom samples were obtained both during 394 
active hypercortisolism (7273±1263 bp.) and after remission (7870±1039 bp.). 3B: TL increased in 10/15 395 
patients, increasing age. The dotted line shows the detection limit of the Southern Blot technique. 396 
*Abbreviations: bp. base pairs; CS. Cushing's syndrome 397 
 398 
 399 
 400 
 401 
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 402 
TABLES:  403 
Table 1. Baseline characteristics of patients with Cushing’s syndrome (CS) and controls. Data are presented 404 
as % and mean ± SD. 405 
 CS (n=77) Controls (n=77) p 
Age (years) 48.6± 12.8 48.4± 12.6 NS 
Smokers 24.7% 19.4% NS 
Alcohol consumption 26% 27.3% NS 
Diabetes mellitus (type 2)  14.3% 1.4% <0.05 
Arterial hypertension 57.1% 12.9% <0.001 
Dyslipidemia  45.5% 20.0% <0.05 
Osteoporosis 29.9% 2.9% <0.001 
Psychiatric history 37.7% 11.4% <0.001 
Body mass index (kg/m2) 28 ± 5.6 26.4 ± 4.9 <0.05 
Waist to hip ratio  0.92±0.07 0.85±0.07 <0.05 
24h urinary free cortisol 
(nmol/24 hours) 
266±180 132±59 <0.001 
Morning serum cortisol 
(nmol/l) 
450±259 375±120 <0.05 
Leukocytes (x10
9
/l) 7.3±2.3 5.8±1.7 <0.05 
Neutrophils (x10
9
/l) 4.4±2.0 3.5±1.2 <0.05 
Lymphocytes (x10
9
/l) 2.1±0.8 1.9±0.4 NS 
 406 
Table 2.  Total leukocyte counts and leukocyte main subsets distribution (neutrophils and lymphocytes) of 407 
Cushing’s syndrome (CS) patients during active disease and remission and their matched controls. Data are 408 
expressed as mean±SD. 409 
 CS  Controls  p 
-Leukocytes in active disease  
(x10
9
/l) (n=21): 
      .neutrophils (%) 
      .lymphocytes (%) 
8.8 ± 2.3 
 
64.7 ± 11.0 
24.5 ± 9.1 
5.9 ± 1.4 
 
55.5 ± 6.1 
32.1 ± 7.8 
<0.01 
 
<0.05 
<0.05 
-Leukocytes in cured patients 
without adrenal insufficiency 
(x10
9
/l) (n=41): 
      .neutrophils (%) 
      .lymphocytes (%) 
 
-Leukocytes in cured patients with 
adrenal insufficiency (x10
9
/l) 
(n=15): 
      .neutrophils (%) 
      .lymphocytes (%) 
 
6.7 ± 2.1 
 
57.1± 8.2 
31.1 ± 6.6 
 
 
6.6 ± 1.5 
 
58.3 ± 8.7 
29.6 ± 9.6 
 
5.8 ± 1.8 
 
54.9 ± 13.8 
30.9 ± 7.1 
 
 
6.2 ± 2.1 
 
52.5 ± 7.7 
34.5 ± 6.6 
 
<0.05 
 
NS 
NS 
 
 
NS 
 
NS 
NS 
*Abbreviations: bp. base pairs  410 
 411 
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Figure 1. Telomere length (TL ) in the whole group of Cushing's syndrome (CS) patients and controls 412 
(7667±1260 vs 7483±1214 bp.), as well as in patients with active CS (7943±1309 vs 7230±1591 bp.), cured 413 
CS without (7510±1219 vs 7639±1335 bp.) or with adrenal insufficiency (AI) (7727±1323 vs 7394±1411 414 
bp.) compared with their respective matched controls. No differences were observed.   415 
 416 
* Abbreviations: CS, Cushing's syndrome; AI, adrenal insufficiency; TL, telomere length 417 
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Figure 2. Telomere length in relation to age in patients with Cushing’s syndrome (•) and controls (◦). 418 
Telomere length is shortened with advancing age in both CS (R = -0.400, p <0.001) and controls (R = -0.292, 419 
p <0.01).  420 
 421 
*Abbreviations: bp. base pairs. 422 
23 
Figure 3. A: Changes in telomere length (TL) in 15 patients in whom samples were obtained both during 423 
active hypercortisolism (7273±1263 bp.) and after remission (7870±1039 bp.). 3B: TL increased in 10/15 424 
patients, increasing age. The dotted line shows the detection limit of the Southern Blot technique.  425 
 426 
 427 
 428 
 429 
*Abbreviations: bp. base pairs; CS. Cushing's syndrome430 
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